Last reviewed · How we verify

NCT04166539

Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty

Completed Last updated 8 December 2021
What this trial tests

trial testing Questionnaires in Metallosis in 115 participants. Completed in 27 September 2021.

Timeline
1 October 2019
Primary endpoint
27 September 2021
27 September 2021

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment115
Start date1 October 2019
Primary completion27 September 2021
Estimated completion27 September 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Adults 18 to 100, any sex, with Metallosis or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to understand whether patients who previously had total hip or total knee replacement experience memory, thinking or heart problems. This study will help us determine if and how often these problems occur.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Blood metal concentrations and cardiac structure and function in total joint arthroplasty patients.
    Brennan PC, Peterson SM, O'Byrne TJ, Laporta ML, et al · · 2024 · cited 5× · PMID 39165877 · DOI 10.5312/wjo.v15.i8.773

Verify or expand the search:

Other trials of Questionnaires

Trials testing the same drug.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04166539.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing